Fractional CMO for companies approaching their next value inflection point
I define the development strategy, take CMO-level ownership and lead the execution.
I help biotech, medtech and specialty pharma companies turn scientific assets into enterprise value — by defining the development path, the value inflection points and leading the organisation that delivers them.
At critical moments, clinical development is not only about execution.
It is about:
- making the risk–return logic visible
- aligning the programme with financing and partnering strategy
- creating a path that is credible to regulators, investors and future commercial organisations
I step in at CMO level to take end-to-end responsibility — from value thesis to operational delivery.
Where I typically create most value:
- Defining development strategies that are scientifically robust, operationally feasible and aligned with the company’s capital situation and next value event
- Turning data packages into programmes that support confident internal decisions and credible external guidance
- Leading regulatory interactions, study design and governance with full ownership of timelines, risk and outcomes
- Building Medical Affairs as a lifecycle value driver — not a support function
Engagement models
Engagements can be structured as ongoing fractional leadership, defined value-inflection projects, hour banks or temporary executive assignments — onsite or remote across the Nordic region and selected EU markets.
Typical situations where I am brought in:
- Approaching a first clinical study or a new development phase where the programme must become investable and decision-ready
- Preparing for the next value inflection point — financing, partnering, portfolio prioritisation or launch
- Translating an existing data package into a development strategy with a clear and credible path to value
- Adding CMO-level capacity during periods of high complexity, rapid scaling or organisational change
- Building or strengthening a Medical Affairs function ahead of launch or geographic expansion
- Ensuring that high-stakes scientific and promotional materials are decision-ready, compliant and supported by an efficient review process
Selected experience
- CMO of orthopaedic biotech
- Senior Director, Global Clinical Development, Novo Nordisk
- Leadership of global Phase I–IV programmes
- Built Medical Affairs organisations in multiple international companies